Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 97

Sort by

Sort Order Select

Journal Articles

Characteristics, Outcomes, Tfr Rates in Young Adults with Chronic Myeloid Leukemia in the Tyrosine Kinase Inhibitor Era: A French Observational Study

Blood (2023) 142 (Supplement 1): 1800.

https://doi.org/10.1182/blood-2023-173132

Published: 2023

Journal Articles

Evaluation of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent Low Risk Del(5q) MDS Patients. Final Results of Sintra-REV Phase III International Multicenter Clinical Trial

Blood (2022) 140 (Supplement 1): 1109–1111.

https://doi.org/10.1182/blood-2022-168718

Published: 2022

Journal Articles

Long-Term Evolution of Somatic Mutations in Patients with Del(5q) MDS Early Treated with Lenalidomide in the Sintra-Rev Clinical Trial: Safe and Effecitive Approach?

Blood (2022) 140 (Supplement 1): 9740–9743.

https://doi.org/10.1182/blood-2022-168599

Published: 2022

Journal Articles

Efficacy of Ropeginterferon Alpha 2b in Inducing Treatment Free Remission in Chronic Myeloid Leukemia - an International, Randomized Phase III Trial (ENDURE, CML-IX) of the German CML-Study Group

Blood (2022) 140 (Supplement 1): 1501–1503.

https://doi.org/10.1182/blood-2022-169324

Published: 2022

Journal Articles

Management of MDS with Isolated Del(5q) Patients in the European MDS (EUMDS) Registry: A Report on 197 Cases

Blood (2022) 140 (Supplement 1): 9802–9803.

https://doi.org/10.1182/blood-2022-167716

Published: 2022

Journal Articles

Last Interim Results of the Real-Life Study Evaluating the Efficacy and Safety of Ponatinib "Topase” in Patients with TKI-Resistant or Intolerant CML

Emilie Cayssials, Gabriel Etienne, Ali G Turhan, Philippe Rousselot, Valerie Coiteux, Marc G. Berger, Francoise Huguet, Agnes Guerci-Bresler

Blood (2022) 140 (Supplement 1): 6776–6777.

https://doi.org/10.1182/blood-2022-166111

Published: 2022

Journal Articles

Treatment Free Survival (TFS) in Patients (pts) with Chronic Myeloid Leukemia (CML) Carrying Atypical BCR-ABL1 Fusion Transcripts: The French CML Group (Fi-LMC) Experience

Hyacinthe Johnson-Ansah, Aude Charbonnier, Delphine Rea, Gabriel Etienne, Lydia Roy, Laurence Legros, Agnes Guerci Bresler, Anne Bouvier, Emilie Cayssials, Valerie Coiteux, Philippe Rousselot, Stephanie Dulucq, Sandrine Hayette, Francois-Xavier Mahon, Franck E. Nicolini

Blood (2021) 138 (Supplement 1): 3604.

https://doi.org/10.1182/blood-2021-147537

Published: 2021

Journal Articles

Management of MDS with Isolated Del(5q) Patients in the European MDS (EUMDS) Registry, a Unique Prospective Real-World Dataset

Blood (2021) 138 (Supplement 1): 4671.

https://doi.org/10.1182/blood-2021-150322

Published: 2021

Journal Articles

Treatment-Free Remissions in Newly Diagnosed CP CML Patients Treated with the Combination of Nilotinib + Pegylated Interferon Alpha 2a Versus Nilotinib Alone in the National Phase III Petals Trial

Blood (2021) 138 (Supplement 1): 2553.

https://doi.org/10.1182/blood-2021-146412

Published: 2021

Journal Articles

Red Blood Cell Transfusion Burden in Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS): A Retrospective Multicenter Study By the Groupe Francophone Des Myélodysplasies (GFM)

Claire Jouzier, Amina Cherait, Pascale Cony-Makhoul, MD, Sylvain Thepot, MD, Thomas Cluzeau, MD PhD, Aspasia Stamatoulas Bastard, MD, Pierre Peterlin, MD, Agnes Guerci Bresler, MD, Sophie Dimicoli-Salazar, MD, Gian-Matteo Pica, MD, Stephane Cheze, MD, Clémence Santana, MD, Fatiha Chermat, Pierre Fenaux, MD PhD, Sophie Park, MD PhD

Blood (2020) 136 (Supplement 1): 42–43.

https://doi.org/10.1182/blood-2020-138722

Published: 2020

Journal Articles

Phase 3 Study of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent (TD) Low Risk Del(5q) MDS Patients - Interim Analysis of the European Sintra-REV Trial

Blood (2020) 136 (Supplement 1): 28–29.

https://doi.org/10.1182/blood-2020-140339

Published: 2020

Journal Articles

Very Long Term Follow up a Phase II Study of Post-Remission Subcutaneous (SC) Azacitidine (AZA) in Patients with AML Post-MDS or Higher-Risk (HR) MDS

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-137012

Published: 2020

Journal Articles

Prospective Evaluation of ABL Kinase Domain Mutational Analysis By Next-Generation-Sequencing in Newly Diagnosed CP CML Patients Undergoing First-Line Treatment with Nilotinib Alone or Nilotinib + Pegylated Interferon-α2a in a Prospective Phase III Trial

Hugues de Lavallade, MD PhD, Sophie Jackson, BSc, Aytug Kizilors, PhD, Gabriel Etienne, MD PhD, Francoise Huguet, MD, Agnes Guerci-Bresler, MD PhD, Delphine Rea, MD, Claudine Chollet, MSc, Stephane Morisset, BioStat, Fanny Robbesyn, BSc, Francois-Xavier Mahon, MD PhD, Stephanie Dulucq, PharmD, PhD, Franck E Nicolini, MD PhD

Blood (2019) 134 (Supplement_1): 664.

https://doi.org/10.1182/blood-2019-125108

Published: 2019

Journal Articles

The TKI-Free Duration after a First Discontinuation Attempt That Failed in CP CML Patients Is a Predictive Factor of TKI-Free Remission after a Second Attempt

Laurence Legros, MD PhD, Franck E Nicolini, MDPhD, Gabriel Etienne, MD PhD, Philippe Rousselot, MDPhD, Delphine Rea, MD, Stephane Giraudier, MD PhD, Agnès Guerci, MD PhD, Francoise Huguet, MD, Martine Gardembas, MD, Jean-Christophe Ianotto, MD PhD, Martine Escoffre-Barbe, MD, Valerie Coiteux, MD, Bruno Varet, MD, Stephane Morisset, BioStat, Francois-Xavier Mahon, MD PhD

Blood (2019) 134 (Supplement_1): 28.

https://doi.org/10.1182/blood-2019-123719

Published: 2019

Journal Articles

Prognostication of Molecular Relapses after Dasatinib or Nilotinib Discontinuation in Chronic Myeloid Leukemia (CML): A FI-LMC STOP 2G-TKI Study Update

Delphine Rea, MD, Franck E Nicolini, MDPhD, Michel Tulliez, MD, Philippe Rousselot, MDPhD, Martine Gardembas, MD, Gabriel Etienne, MD PhD, Francois Guilhot, MD, Joelle Guilhot, PhD, Agnès Guerci, MD PhD, Martine Escoffre-Barbe, MD, Laurence Legros, MD PhD, Bruno Villemagne, MD, Gaëlle Guillerm, MD, Marie-Pierre Noel, MD, Valerie Coiteux, MD, Jean-Michel Pignon, MD, Francois-Xavier Mahon, MD PhD

Blood (2019) 134 (Supplement_1): 30.

https://doi.org/10.1182/blood-2019-124408

Published: 2019

Journal Articles

The Combination of Nilotinib + Pegylated IFN Alpha 2a Provides Somewhat Higher Cumulative Incidence Rates of MR4.5 at M36 Versus Nilotinib Alone in Newly Diagnosed CP CML Patients. Updated Results of the Petals Phase III National Study.

Blood (2019) 134 (Supplement_1): 494.

https://doi.org/10.1182/blood-2019-123674

Published: 2019

Journal Articles

Interim Results of the Real-Life Study Evaluating the Efficacy and Safety of Ponatinib "Topase" Reveals Induction of Early Molecular Responses in Patients with TKI-Resistant or Intolerant CML

Agnès Guerci, MD PhD, Emilie Cayssials, MD, Philippe Rousselot, MD PhD, Francoise Huguet, MD, Valerie Coiteux, MD, Marc G. Berger, MD PhD, Gabriel Etienne, MD PhD, Ali G Turhan, MD PhD

Blood (2019) 134 (Supplement_1): 5908.

https://doi.org/10.1182/blood-2019-122769

Published: 2019

Journal Articles

Characteristics and Outcome of Older Patients with Acute Promyelocytic Leukemia Front-Line Treated with or without Arsenic Trioxide — an International Collaborative Study

Blood (2018) 132 (Supplement 1): 80.

https://doi.org/10.1182/blood-2018-99-111768

Published: 2018

Journal Articles

Excess Mortality in Low-Risk MDS Can be Explained By MDS and AML Related Causes of Death

Blood (2018) 132 (Supplement 1): 4385.

https://doi.org/10.1182/blood-2018-99-115928

Published: 2018

Journal Articles

MDS Diagnosis: Many Patients May Not Require Bone Marrow Examination

Blood (2018) 132 (Supplement 1): 4357.

https://doi.org/10.1182/blood-2018-99-111838

Published: 2018

NARROW

Characteristics, Outcomes, Tfr Rates in Young Adults with Chronic Myeloid Leukemia in the Tyrosine Kinase Inhibitor Era: A French Observational Study

Evaluation of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent Low Risk Del(5q) MDS Patients. Final Results of Sintra-REV Phase III International Multicenter Clinical Trial

Long-Term Evolution of Somatic Mutations in Patients with Del(5q) MDS Early Treated with Lenalidomide in the Sintra-Rev Clinical Trial: Safe and Effecitive Approach?

Efficacy of Ropeginterferon Alpha 2b in Inducing Treatment Free Remission in Chronic Myeloid Leukemia - an International, Randomized Phase III Trial (ENDURE, CML-IX) of the German CML-Study Group

Management of MDS with Isolated Del(5q) Patients in the European MDS (EUMDS) Registry: A Report on 197 Cases

Last Interim Results of the Real-Life Study Evaluating the Efficacy and Safety of Ponatinib "Topase” in Patients with TKI-Resistant or Intolerant CML

Treatment Free Survival (TFS) in Patients (pts) with Chronic Myeloid Leukemia (CML) Carrying Atypical BCR-ABL1 Fusion Transcripts: The French CML Group (Fi-LMC) Experience

Management of MDS with Isolated Del(5q) Patients in the European MDS (EUMDS) Registry, a Unique Prospective Real-World Dataset

Treatment-Free Remissions in Newly Diagnosed CP CML Patients Treated with the Combination of Nilotinib + Pegylated Interferon Alpha 2a Versus Nilotinib Alone in the National Phase III Petals Trial

Red Blood Cell Transfusion Burden in Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS): A Retrospective Multicenter Study By the Groupe Francophone Des Myélodysplasies (GFM)

Phase 3 Study of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent (TD) Low Risk Del(5q) MDS Patients - Interim Analysis of the European Sintra-REV Trial

Very Long Term Follow up a Phase II Study of Post-Remission Subcutaneous (SC) Azacitidine (AZA) in Patients with AML Post-MDS or Higher-Risk (HR) MDS

Prospective Evaluation of ABL Kinase Domain Mutational Analysis By Next-Generation-Sequencing in Newly Diagnosed CP CML Patients Undergoing First-Line Treatment with Nilotinib Alone or Nilotinib + Pegylated Interferon-α2a in a Prospective Phase III Trial

The TKI-Free Duration after a First Discontinuation Attempt That Failed in CP CML Patients Is a Predictive Factor of TKI-Free Remission after a Second Attempt

Prognostication of Molecular Relapses after Dasatinib or Nilotinib Discontinuation in Chronic Myeloid Leukemia (CML): A FI-LMC STOP 2G-TKI Study Update

The Combination of Nilotinib + Pegylated IFN Alpha 2a Provides Somewhat Higher Cumulative Incidence Rates of MR4.5 at M36 Versus Nilotinib Alone in Newly Diagnosed CP CML Patients. Updated Results of the Petals Phase III National Study.

Interim Results of the Real-Life Study Evaluating the Efficacy and Safety of Ponatinib "Topase" Reveals Induction of Early Molecular Responses in Patients with TKI-Resistant or Intolerant CML

Characteristics and Outcome of Older Patients with Acute Promyelocytic Leukemia Front-Line Treated with or without Arsenic Trioxide — an International Collaborative Study

Excess Mortality in Low-Risk MDS Can be Explained By MDS and AML Related Causes of Death

MDS Diagnosis: Many Patients May Not Require Bone Marrow Examination

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only